We wanted 80% of stroke patients to have a completed ... and a 5-point Likert scale (1 = weak belief, 5 = strong belief) to measure staff nurse beliefs. Participants were encouraged to be open ...

The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

Intra-arterial thrombolysis via urokinase following reperfusion by endovascular thrombectomy for stroke does not affect survival without disability.

For patients with acute ischemic stroke whose symptoms began 4.5 to 24 hours earlier, alteplase is associated with a higher percentage of patients achieving a score of 0 or 1 on the modified Rankin ...

When scaled up and sustained over time, the simple intervention of salt substitution could improve secondary stroke ...

4.9%, 6.3%]). Similar effects were observed in an exploratory analysis based on age, gender, and baseline National Institute of Health Stroke Scale score. “Today’s approval is a significant ...

The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.

included 18 adults who were 6 to 60 months post-ischemic subcortical middle cerebral arterial stroke and recorded a Modified Rankin Scale score of 3 or 4. All participants were transplanted with 2 ...

For patients with large vessel occlusion presenting between 4.5 and 24 hours, intra-arterial tenecteplase after successful thrombectomy results in improved likelihood of excellent outcome (modified ...

Phase III PRESTIGE-AF trial shows that direct oral anticoagulants significantly lower the risk of ischemic stroke in ...

TUESDAY, Feb. 18, 2025 (HealthDay News) -- For patients with acute ischemic stroke (AIS) whose symptoms began 4.5 to 24 hours earlier ... 1 on the modified Rankin scale at 90 days, according ...